QNZ (EVP4593): A Nanomolar Quinazoline NF-κB Inhibitor for Inflammation and Neurodegenerative Disease Research

Executive Summary: QNZ (EVP4593) is a potent inhibitor of NF-κB transcriptional activation, exhibiting an IC₅₀ of 11 nM in Jurkat T cells and 7 nM for TNF-α inhibition (APExBIO, product page). It is a quinazoline derivative identified via luciferase reporter assays and is insoluble in water but highly soluble in DMSO and ethanol. QNZ is effective in attenuating store-operated calcium entry (SOC) in neuronal cultures at 300 nM, relevant for Huntington’s disease models (internal link). Research demonstrates anti-inflammatory efficacy in vivo, including edema reduction in rat models. The compound enables reproducible, high-sensitivity NF-κB pathway studies for translational and basic science applications (see also related article).

Biological Rationale

NF-κB is a central transcription factor regulating inflammation, immunity, and cell survival. Dysregulation of NF-κB signaling contributes to chronic inflammation, fibrosis, and neurodegenerative diseases such as Huntington’s disease (HD) (Yang et al., 2025). In osteomyelitis and persistent skeletal infections, NF-κB-driven immune responses and fibrosis contribute to treatment resistance and tissue damage. Targeting this pathway can modulate both inflammatory and fibrotic outcomes, as shown in EGFR/mTOR axis modulation studies (DOI). Small molecule inhibitors like QNZ (EVP4593) address the need for specific, high-affinity NF-κB inhibition in research models.

Mechanism of Action of QNZ (EVP4593)

QNZ (EVP4593) is a quinazoline derivative that directly inhibits NF-κB transcriptional activation. It interrupts the nuclear translocation of NF-κB subunits, thereby preventing their DNA binding and subsequent gene expression. In Jurkat T cells, QNZ demonstrates an IC₅₀ of 11 nM for NF-κB inhibition and 7 nM for suppression of TNF-α production. It does not act as a general cytotoxin at nanomolar concentrations, preserving cell viability in multiple models. The compound also attenuates PMA/PHA-induced NF-κB activation and inhibits store-operated calcium entry (SOC) in neuronal models at 300 nM. This mechanism is relevant for studying both inflammatory signaling and calcium dysregulation implicated in neurodegeneration (internal link—this article further details workflow integration and data interpretation).

Evidence & Benchmarks

• QNZ (EVP4593) inhibits NF-κB activation in human Jurkat T cells with an IC₅₀ of 11 nM (APExBIO datasheet, product page).
• Suppresses TNF-α production with an IC₅₀ of 7 nM in cell-based assays (APExBIO, source).
• Demonstrates anti-inflammatory effects by reducing edema in a rat carrageenin-induced paw edema model (internal).
• Attenuates store-operated calcium entry (SOC) influx in primary neuronal cultures at 300 nM, relevant to HD pathology (source).
• No significant toxicity observed in Drosophila Huntington’s disease (HD) models, while slowing progressive motor decline (internal).
• Mechanistic studies in related fibrotic and inflammatory models highlight the importance of NF-κB/EGFR-mTOR axis modulation in mitigating fibrosis and enhancing antibiotic efficacy against S. aureus (Yang et al., 2025).

Applications, Limits & Misconceptions

QNZ (EVP4593) is widely used to study:

• NF-κB pathway modulation in immune, epithelial, and neuronal cells.
• Inflammatory disease models (e.g., edema, infection, autoimmunity).
• Neurodegenerative pathways (e.g., Huntington’s disease) involving SOC and calcium influx.
• Fibrosis and tissue remodeling mechanisms relevant to chronic infection and wound healing.

This article extends the workflow practices described in QNZ (EVP4593): Practical Strategies for Reliable NF-κB Inhibition by providing additional structured evidence and clarification of mechanistic boundaries.

Common Pitfalls or Misconceptions

• QNZ is not water-soluble; improper solvent choice can yield unreliable dosing (source).
• Long-term storage of QNZ stock solutions at room temperature leads to degradation; always store at -20°C and minimize freeze-thaw cycles.
• QNZ is not a pan-cytotoxin; observed effects at nanomolar concentrations are pathway-specific and not due to general cell death.
• Does not directly target bacterial or viral pathogens—effects are mediated through host cell signaling inhibition.
• Not suitable for in vivo applications where water solubility or systemic delivery is mandatory, unless appropriate formulation is used.

Workflow Integration & Parameters

For experimental use, dissolve QNZ (EVP4593) in DMSO (≥15.05 mg/mL) or ethanol (≥10.06 mg/mL with ultrasonic assistance). For optimal solubility, warming to 37°C and ultrasonic shaking are recommended. Prepare fresh stock solutions and store at -20°C; avoid long-term storage in solution form. In neuronal cultures, 300 nM QNZ is used to inhibit SOC influx. For anti-inflammatory cell assays, IC₅₀ values of 7–11 nM define effective concentration ranges. Always validate dosing in the target cell type and context (QNZ (EVP4593) product details).

For further context on integrating QNZ into translational workflows, see Redefining Translational Research: QNZ (EVP4593) and the Inflammation-Fibrosis Axis, which discusses the interplay between NF-κB inhibition, fibrosis, and infection control—extending the mechanistic and translational guidance covered here.

Conclusion & Outlook

QNZ (EVP4593), provided by APExBIO (SKU: A4217), is a validated, high-affinity inhibitor of NF-κB transcriptional activation. Its nanomolar potency, pathway specificity, and reproducible performance make it a preferred tool for studies of inflammation, immune modulation, fibrosis, and neurodegeneration. Ongoing research underscores its value in dissecting complex signaling interactions and evaluating candidate therapies in preclinical models. For further technical details, refer to the official product page.